openPR Logo
Press release

Cancer Biomarkers Market is Poised to Reach USD 34 Billion with a CAGR of 12% by 2032

05-21-2024 05:49 AM CET | Health & Medicine

Press release from: Fact.MR

Cancer Biomarkers Market

Cancer Biomarkers Market

According to a recent Fact.MR analysis, the global market for cancer biomarkers is predicted to approach $34 billion by 2032, a threefold increase over 2022. The market is currently valued slightly more than US$11 billion. During the forecast period, the worldwide cancer biomarker market is expected to rise at an astounding 12% CAGR. The increased incidence of disabling malignancies is boosting growth potential.

Key market participants focused their efforts on R&D to create novel and reliable biomarkers for improved diagnosis and treatment. According to the National Cancer Institute (NCI), national spending on cancer care has totaled USD 156 billion throughout history.

Collaborations between various key industry players and research institutes to discover novel cancer biomarkers for personalized treatment are also projected to fuel market expansion over the forecast period.

Get Sample PDF of this report at:
https://www.factmr.com/connectus/sample?flag=S&rep_id=4587

Many pharmaceutical companies are making significant investments in the discovery and development of new biomarkers for cancer detection and treatment. Many potential contenders are reaching the conclusion of their development cycle and are expected to deliver a big boost to the market when they launch.

Key Takeaways from the Market Study

The European cancer biomarkers market is estimated to develop at a CAGR of over 11.6% during the forecast period.
North America is the world's largest market for cancer biomarkers, accounting for more than 40% of the total.
PSA cancer biomarker testing will account for approximately half of global market revenue.
APAC will emerge as a lucrative market, with a 12% value CAGR until 2032.

"As organizations seek to modernize Cancer Biomarkers This is helping them reduce operational costs, eliminate complexity and increase data consistency across disparate platforms," says a Fact.MR Analyst

Furthermore, the introduction of multiple assay-based techniques and novel technologies for prostate cancer screening has driven up demand for PSA testing.

The breast cancer sector had the greatest share in 2021. Factors such as a growth in the global incidence of cancer, as well as an increase in the number of different types of biomarkers, including those based on cutting-edge technology.

Competitive landscape

Cancer biomarkers operate in a highly competitive global market. The top three corporations control roughly half of the market. F. Hoffmann-La Roche Ltd. is a key player in the cancer biomarkers sector, offering a diverse variety of tumor biomarker tests. Here are some important developments:

Hoffmann-La Roche Ltd. (Switzerland) introduced the Elecsys Anti-p53 immunoassay in April 2021 to aid in the diagnosis of various cancers.
In December 2020, Thermo Fisher Scientific (US) got FDA approval for an NGS-based companion diagnostic for non-small cell lung cancer tumor tissue with the EGFR Exon20 insertion mutation.

Qiagen N.V. (Netherlands) introduced therascreen BRAF as a companion diagnostic to a BRAFTOVI (encorafenib)-based treatment in metastatic colorectal cancer in April 2020.

The cancer biomarkers market in Europe is predicted to expand significantly over the forecast period, driven by an increase in the number of occurrences of lung cancer. Lung cancer biomarkers include CYFRA 21-1, Plasma Kallikrein (KLKB1), Serum Amyloid A (SAA), Haptoglobin ฮฒ Chain (Hp ฮฒ), Complement Component 9 (C9), Endoglin (CD105), Peroxiredoxin 1 (PRX1), and Pro-gastrin-releasing Peptide (program).

๐†๐ž๐ญ ๐‚๐ฎ๐ฌ๐ญ๐จ๐ฆ๐ข๐ณ๐š๐ญ๐ข๐จ๐ง ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐Ÿ๐จ๐ซ ๐’๐ฉ๐ž๐œ๐ข๐Ÿ๐ข๐œ ๐‘๐ž๐ฌ๐ž๐š๐ซ๐œ๐ก ๐’๐จ๐ฅ๐ฎ๐ญ๐ข๐จ๐ง๐ฌ:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=4587

Many players are performing considerable research to identify key epigenetic alterations associated with cancer in order to create diagnostics and cancer-targeting medicines. Increased collaboration among pharmaceutical companies to develop novel treatments targeting epigenetic biomarkers is projected to boost growth in this market.

Key Segments Covered in the Cancer Biomarkers Industry Report

Cancer Biomarkers by Test Type
PSA
CTC
AFP
CA
HER2
BRCA
ALK
CEA
EFGR Mutation
KRAS Mutation
Other
Cancer Biomarkers by Illness Indication
Blood
Prostat
Ovarian
Stomach
Liver
Other
Cancer Biomarkers by Region
North America
Latin America
Europe
Asia Pacific
Middle East & Africa

๐‘๐ž๐š๐ ๐Œ๐จ๐ซ๐ž: https://www.factmr.com/report/4587/cancer-biomarkers-market

More Valuable Insights

Fact.MR, in its new offering, presents an unbiased analysis of the global cancer biomarkers market, presenting historical analysis from 2015 to 2021 and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of test type (PSA tests, CTC tests, AFP tests, CA tests, HER2 tests, BRCA tests, ALK Tests, CEA tests, EFGR mutation tests, KRAS mutation tests and others) and by illness indication (blood cancer, prostate cancer, ovarian cancer, stomach cancer, liver cancer and others) across five major regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

๐‚๐จ๐ง๐ญ๐š๐œ๐ญ:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

๐€๐›๐จ๐ฎ๐ญ ๐…๐š๐œ๐ญ.๐Œ๐‘

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cancer Biomarkers Market is Poised to Reach USD 34 Billion with a CAGR of 12% by 2032 here

News-ID: 3504748 • Views: โ€ฆ

More Releases from Fact.MR

Smartwatches Market Expected to Grow at 17.8% CAGR, Reaching US$ 121.5 Billion by 2032
Smartwatches Market Expected to Grow at 17.8% CAGR, Reaching US$ 121.5 Billion b โ€ฆ
The global smartwatches market, valued at US$ 23.5 billion in 2022, is forecasted to surge to US$ 121.5 billion by 2032, according to a revised study by Fact.MR. The market is expected to experience remarkable growth at a CAGR of 17.8% through the forecast period. Apple maintains dominance in the smartwatch sector, having consistently led in unit sales since the launch of its first watch in 2015. Despite expectations favoringโ€ฆ
Global Marketing Automation Market Expected to Grow at 12.3% CAGR through 2032
Global Marketing Automation Market Expected to Grow at 12.3% CAGR through 2032
The global marketing automation market is expected to grow at a robust CAGR of 12.3% from 2022 to 2032. By the end of 2032, the market share of marketing automation is forecasted to reach US$ 15.7 billion, up significantly from US$ 4.9 billion in 2022. The marketing automation market is poised for substantial growth up to 2027, driven by the increasing prevalence of mobile phones. As businesses embrace digital transformation andโ€ฆ
Private Investigation Services Market Projected to Reach US$ 28.2 Billion by 2032
Private Investigation Services Market Projected to Reach US$ 28.2 Billion by 203 โ€ฆ
The global private investigation services market was valued at US$ 18.2 billion in 2022 and is projected to grow steadily at a compound annual growth rate (CAGR) of 4.5% from 2022 to 2032. This growth trajectory is fueled by the increasing integration of technology into investigative services and a rising incidence of financial fraud globally. The private investigation industry shows promising prospects due to heightened instances of various frauds worldwide. Increasingโ€ฆ
Pet Wearables Market to Grow at 8% CAGR from 2022 to 2032
Pet Wearables Market to Grow at 8% CAGR from 2022 to 2032
During the forecast period of 2022-2032, the pet wearables market is anticipated to grow at a compound annual growth rate (CAGR) of 8%, according to Fact.MR. By 2032, the global market for pet wearables is projected to reach a valuation of US$ 10.96 billion. This growth is largely driven by consumers' increasing spending on pet healthcare and biomedical imaging. Additionally, the rapid expansion of pet insurance companies in recent yearsโ€ฆ

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by โ€ฆ
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emergingโ€ฆ
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio โ€ฆ
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boostโ€ฆ
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p โ€ฆ
Global Oncology Nutrition Market: Overview Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strengthโ€ฆ
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve โ€ฆ
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:โ€ฆ
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance โ€ฆ
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launchโ€ฆ
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C โ€ฆ
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on topโ€ฆ